drugset / Trial / NCT02316847

An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray.

NCT02316847

Phase 2 Terminated 126 enrolled Acorda Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess long-term safety and tolerability of repeat dose diazepam nasal spray in adolescents and adults with cluster seizures, with a focus on potential local effects (changes in nasal mucosa, olfaction, and taste).

Timeline

Start
2014-12
Primary completion
2016-07
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Diazepam Small molecule Intranasal

Indications